- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target ; volume:14 ; number:1 ; day:15 ; month:9 ; year:2021 ; pages:1-17 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (15.9.2021), 1-17, 12.2021
- Urheber
-
Qian, Wenjing
Zhao, Mingfang
Wang, Ruoyu
Li, Heming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01161-8
- URN
-
urn:nbn:de:101:1-2021112700342009123364
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Qian, Wenjing
- Zhao, Mingfang
- Wang, Ruoyu
- Li, Heming
- SpringerLink (Online service)
Ähnliche Objekte (12)
Next generation of immune checkpoint inhibitors and beyond
Resistance to immune checkpoint inhibitors. Next steps and combinational approaches
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Next generation of immune checkpoint inhibitors and beyond
Resistance to immune checkpoint inhibitors. Next steps and combinational approaches
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Next generation of immune checkpoint inhibitors and beyond
Resistance to immune checkpoint inhibitors. Next steps and combinational approaches
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition